MediciBioㅣ메디치바이오

Oligonucleotide-based or peptide-based drugs are rapidly eliminated from blood circulation after administration, attributable to their short in vivo half-lives; therefore, large amount of drug administration is necessary to show sufficient in vivo efficacy. Our Medici Peptide is developed to efficiently bind to albumin in vivo, and Medici Peptide-Drug Conjugate (MDC) can therefore increase retention time of oligonucleotide or peptide in blood circulation resulting in enhanced efficacy, and further maintain long-term in vivo efficacy by steady release of drugs from the biodegradable linker.

Development of COVID-19 vaccine served as a momentum to pay attention to an ionizable lipid which is a core component of lipid nanoparticle of mRNA COVID-19 vaccine, as a clinically proven carrier. Although mRNA vaccine market has grown explosively, there is still insufficient supply of carrier technology to fulfill the increasing needs for gene therapeutics. Development of mRNA medicine is also limited due to patent monopoly of biodegradable ionizable lipid carriers including ALC-0315 and SM-102 until 2036. Medici Ionizable Lipid is a novel biodegradable ionizable lipid that avoids the existing patents of ionizable lipids or lipid nanoparticles, which can contribute to development of new gene therapeutics with excellent efficacy and safety.

Not limited to vaccines for infectious diseases, gene therapy has been expanding its scope of development to cancer vaccine, immunotherapy and intractable neuronal disease treatment. However, no distinct non-viral carriers have been developed for targeting other tissues except liver, such as cancer, lung or brain tissues. Therefore, targeted gene therapy shows a great promise as next-generation therapeutics in the field of gene therapy. Our Medici Targeting Lipid enables the delivery of gene-containing lipid nanoparticle to specific tissues including liver, lung, and cancer, contributing to the development of gene therapeutics for diverse clinical indications.

Oligonucleotide-based or peptide-based drugs are rapidly eliminated from blood circulation after administration, attributable to their short in vivo half-lives; therefore, large amount of drug administration is necessary to show sufficient in vivo efficacy. Our Medici Peptide is developed to efficiently bind to albumin in vivo, and Medici Peptide-Drug Conjugate (MDC) can therefore increase retention time of oligonucleotide or peptide in blood circulation resulting in enhanced efficacy, and further maintain long-term in vivo efficacy by steady release of drugs from the biodegradable linker.

Development of COVID-19 vaccine served as a momentum to pay attention to an ionizable lipid which is a core component of lipid nanoparticle of mRNA COVID-19 vaccine, as a clinically proven carrier. Although mRNA vaccine market has grown explosively, there is still insufficient supply of carrier technology to fulfill the increasing needs for gene therapeutics. Development of mRNA medicine is also limited due to patent monopoly of biodegradable ionizable lipid carriers including ALC-0315 and SM-102 until 2036. Medici Ionizable Lipid is a novel biodegradable ionizable lipid that avoids the existing patents of ionizable lipids or lipid nanoparticles, which can contribute to development of new gene therapeutics with excellent efficacy and safety.

Not limited to vaccines for infectious diseases, gene therapy has been expanding its scope of development to cancer vaccine, immunotherapy and intractable neuronal disease treatment. However, no distinct non-viral carriers have been developed for targeting other tissues except liver, such as cancer, lung or brain tissues. Therefore, targeted gene therapy shows a great promise as next-generation therapeutics in the field of gene therapy. Our Medici Targeting Lipid enables the delivery of gene-containing lipid nanoparticle to specific tissues including liver, lung, and cancer, contributing to the development of gene therapeutics for diverse clinical indications.

PIPELINE

MDC-001

Medici Peptide for delivery of oligonucleotides (siRNA/ASO) and peptides

MDC-002

Medici Ionizable Lipid for efficient mRNA/siRNA-LNP

MDC-004

Medici Targeting Lipid for specific tissue-targeting mRNA/siRNA-LNP

MDC-001 : Medici Peptide for delivery of oligonucleotides (siRNA/ASO) and peptides

MDC-002 : Medici Ionizable Lipid for efficient mRNA/siRNA-LNP

MDC-004 : Medici Targeting Lipid for specific tissue-targeting mRNA/siRNA-LNP